Suzuki Hiroyuki, Owada Yuki, Watanabe Yuzuru, Inoue Takuya, Fukuharav Mitsuro, Yamaura Takumi, Mutoh Satoshi, Okabe Naoyuki, Yaginuma Hiroshi, Hasegawa Takeo, Yonechi Atsushi, Ohsugi Jun, Hoshino Mika, Higuchi Mitsunori, Shio Yutaka, Gotoh Mitsukazu
Department of Regenerative Surgery; Fukushima Medical University; School of Medicine; Fukushima, Japan.
Hum Vaccin Immunother. 2014;10(2):352-7. doi: 10.4161/hv.26919. Epub 2013 Nov 6.
Despite of recent development in the field of molecular targeted therapies, lung cancer is a leading cause of cancer death in the world. Remarkable progress has been made recently in immunotherapy for patients with non-small-cell lung cancer (NSCLC), with several modalities, concepts, and treatment settings being investigated. In vaccine development, large-scale clinical trials such as those with L-BLP25, belagenpumatucel-L, TG4010, and talactoferrin are already ongoing and some results have been reported. A trial of a vaccine as adjuvant therapy for patients with completely resected NSCLC is also ongoing with one of the major cancer-testis antigens, melanoma-associated antigen (MAGE)-A3. More recently, the effectiveness of multiple peptide vaccines has also been shown. Recently developed unique treatment modalities are the immune checkpoint inhibitors, such as antibodies against PD-1 and PD-L1, which also show promise. However, although therapeutic cancer vaccines are generally thought to be safe, severe adverse events should be monitored carefully when using immune checkpoint inhibitors. Here, we discuss recent advances and future perspectives of immunotherapy for patients with NSCLC.
尽管分子靶向治疗领域近期取得了进展，但肺癌仍是全球癌症死亡的主要原因。非小细胞肺癌（NSCLC）患者的免疫治疗最近取得了显著进展，目前正在研究多种治疗方式、概念和治疗方案。在疫苗研发方面，诸如L-BLP25、belagenpumatucel-L、TG4010和乳铁传递蛋白等大规模临床试验已经在进行，并且已经报告了一些结果。一项针对完全切除的NSCLC患者的疫苗辅助治疗试验也正在进行，该疫苗使用的是主要癌症睾丸抗原之一，黑色素瘤相关抗原（MAGE）-A3。最近，多种肽疫苗的有效性也已得到证实。最近开发的独特治疗方式是免疫检查点抑制剂，例如抗PD-1和PD-L1抗体，它们也显示出了前景。然而，尽管治疗性癌症疫苗通常被认为是安全的，但在使用免疫检查点抑制剂时，应仔细监测严重不良事件。在此，我们讨论NSCLC患者免疫治疗的最新进展和未来前景。
